Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) Insider Sells $18,908.10 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Jose Manuel Otero sold 2,115 shares of Lexeo Therapeutics stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $18,908.10. Following the completion of the transaction, the insider directly owned 64,197 shares of the company’s stock, valued at $573,921.18. The trade was a 3.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jose Manuel Otero also recently made the following trade(s):

• On Monday, August 18th, Jose Manuel Otero sold 2,848 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.67, for a total transaction of $13,300.16.

Lexeo Therapeutics Trading Up 9.2%

LXEO opened at $9.58 on Monday. The stock has a 50-day moving average of $5.91 and a 200 day moving average of $4.41. Lexeo Therapeutics, Inc. has a 12 month low of $1.45 and a 12 month high of $11.72. The firm has a market cap of $517.32 million, a P/E ratio of -2.94 and a beta of 1.66.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. On average, research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on LXEO. HC Wainwright lifted their price objective on shares of Lexeo Therapeutics from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Guggenheim began coverage on shares of Lexeo Therapeutics in a research note on Wednesday. They set a “buy” rating and a $30.00 price target for the company. Oppenheimer started coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They set an “outperform” rating and a $20.00 price target on the stock. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Finally, Leerink Partners boosted their target price on Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $18.86.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently added to or reduced their stakes in LXEO. CWM LLC grew its stake in Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after acquiring an additional 6,216 shares in the last quarter. Ethic Inc. purchased a new stake in shares of Lexeo Therapeutics in the second quarter valued at approximately $44,000. Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics in the second quarter valued at approximately $50,000. Intech Investment Management LLC increased its holdings in Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after purchasing an additional 2,342 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Lexeo Therapeutics during the 2nd quarter valued at $60,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.